论文部分内容阅读
血管并发症是2型糖尿病患者致死、致残的主要原因，临床防治困难。钠-葡萄糖协同转运蛋白2抑制剂———达格列净，作为一种新型的降糖制剂，其降糖效果确切，且在降压、调脂、降尿酸等方面发挥一定作用，除此之外，其对糖尿病血管并发症有潜在的益处，能预防和减轻糖尿病心血管并发症发生、发展。深入了解达格列净对2型糖尿病糖脂代谢的作用机制以及其未来的研究方向，有助于达格列净在临床中的应用。“,”Diabetes mellitus vascular complication is the main leading cause of death and disability in patients with type 2 diabetes mellitus.Sodium-glucose cotransporter 2 inhibitors—dapagliflozin, as a novel anti-diabetic agent,not only achieved significant hypoglycemic effect,but also showed the clinical effect on lowering blood pressure,regulating fat and lowering uric acid,besides,it also has some potential benefits for diabetic vascular complications and prevent and reduce the development of diabetic vascular complications . Deep understanding of the action mechanisms of dapagliflozin on glycolipid metabolism and it′s future research directions,is helpful for the clinical application of dapagliflozin .